Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 9/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4176622 | 0.68 | P2RX3 (0.36) | P2RX3MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL16376197 | 0.63 | MEN1 (0.56) | P2RX3MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL738953 | 0.62 | MEN1 (0.54) | P2RX3MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL8928066 | 0.62 | MEN1 (0.54) | P2RX3MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL19173031 | 0.62 | MEN1 (0.54) | P2RX3MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL1801722 | 0.62 | MEN1 (0.54) | P2RX3MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL4312808 | 0.62 | MEN1 (0.54) | P2RX3MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL1632799 | 0.62 | MEN1 (0.54) | P2RX3MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL16005690 | 0.62 | MEN1 (0.54) | P2RX3MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL11024894 | 0.62 | MEN1 (0.54) | P2RX3MEN1KMT2AL3MBTL1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | P2RX3 1640/4885MEN1 3667/4885KMT2A 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.